UCM-1336 is a potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor ( IC50 = 2 μM). UCM-1336 improves survival in Ras-driven acute myeloid leukemia. UCM-1336 significantly impairs the membrane association of the four Ras isoforms, leading to a decrease of Ras activity and to inhibition of Ras downstream signaling pathways. In addition, it induces cell death in a variety of Ras-mutated tumor cell lines and increases survival in an in vivo model of acute myeloid leukemia.
UCM-1336 is a potent ICMT inhibitor, with an IC50 of 2 μM. UCM-1336 induces mislocalization of endogenous Ras, decreases Ras activation and induces cell death by autophagy and apoptosis[1].
